PDCD1 and neoplasm: For instance LAG-3 may promote more tumor-specific responses than currently licensed immunotherapies: concomitant LAG-3/PD-1 expression is mostly restricted to infiltrating TILs, expressed at high levels in murine models (60), and mouse studies into other combinations such as a PKC-η/PD-1 blockade therapy has shown a reduction in T-reg immunosuppressive activity without the concomitant increase in autoimmunity (96).